Gore announced the first clinical use in the USA of the Gore Viabahn Endoprosthesis with heparin bioactive surface on a lower profile delivery system. This device is designed to percutaneously treat superficial femoral artery and iliac peripheral artery disease by relining the native vessel. The first US procedure to treat a patient using the device was performed by Tony Das, director of Peripheral Interventions, Texas Health Presbyterian Hospital Dallas, Texas, USA.
The Gore Viabahn Endoprosthesis with heparin bioactive surface is a next generation device that enables a reduction in delivery profile to 6 Fr for 5 and 6mm devices and 7 Fr for 7 and 8mm devices and is delivered over a 0.018” or 0.014” guidewire. The reduced delivery profile provides interventionalists with greater options for delivery with the same trackability and device performance in treating stenoses and occlusions of the superficial femoral artery and iliac artery. The FDA approved the lower profile device in February 2011.
“The use of covered stents to treat vascular disease has been limited in some patients due to the need for a larger sheath size. That gap between covered stents and bare metal stents has now been bridged. The reduction in French size of the Gore Viabahn Endoprosthesis is a revolutionary advancement giving physicians more options in the treatment of peripheral vascular disease,” commented Das.
This is the only stent-graft approved for use in the superficial femoral artery and iliac artery. The new device is available with a 120cm long delivery catheter and incorporates the Carmeda BioActive Surface, which utilises end-point immobilisation of derivatised heparin to the luminal surface of the endoprosthesis. This proprietary surface technology preserves the heparin bioactive sites such that they remain free to interact with the blood at the device surface without being consumed.